Cenduit LLC
has introduced a new
study simulation and forecasting service
that will enable clinical trial sites to better plan and control supplies for their patients. When integrated with Cenduit’s interactive response technology (IRT) services, the new service will give sponsors complete confidence in their clinical supply chain.
“Clinical trials are more complex than ever and a robust and reliable clinical trial supply strategy is vital to study success,” said Jogin Desai, Cenduit chief executive officer. “The simulation and forecasting models, integrated with the
patient randomization
and
drug allocation
services inherent in our IRT systems, allow the complete coordination of procurement, packaging and logistics, with supply requirements from the sites themselves continuously factored in.”
Desai said the new system helps further minimize the risk of drug supply overage and drug outages at sites and accelerates drug development through increased supply chain productivity. The system also allows clinical trial supply coordinators to test different supply scenarios before implementing them, and to identify in advance the risks associated with any supply strategy.
“By integrating forecasting and simulation parameters into the IRT system, patients will receive the right treatment on time, every time and at the lowest cost,” Desai said.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.